C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Latest News
Government & Policy
Careers and Employment
ACS News
How to log in
Contact Us
Site Map
About C&EN
About the Magazine
How to Subscribe
How to Advertise

Latest News RSS Feed

latest news RSS feedWhat is this?

Join ACS
Join ACS
  Latest News  
  September 13,  2004
Volume 82, Number 37
p. 8


  Pfizer To Pay $835 Million In Asbestos Claims  

  Drugmaker Pfizer says it will pay $430 million to settle asbestos personal injury claims against a subsidiary, Quigley Co. In addition, Pfizer will contribute $405 million to a trust intended to compensate future claimants.

To account for the cost, Pfizer plans to take a $229 million after-tax charge against earnings in the third quarter--the first of several charges to come.

Acquired in 1968 when Pfizer was a more diversified company, Quigley made powdered insulation containing what Pfizer says were small amounts of chrysotile asbestos. The insulation, which the company stopped selling in the early 1970s, was used on pipes, boilers, and furnaces. As of the end of July, Pfizer and Quigley were named as defendants in 171,611 lawsuits, Pfizer says. Quigley's business since 1982 has been to manage its asbestos litigation.

Quigley will file a reorganization plan in U.S. Bankruptcy Court for the Southern District of New York. That plan contains an agreement, between Pfizer and attorneys representing more than 80% of individuals with claims, that provides the $430 million settlement.

The plan will also establish a trust for future claims. If the court and 75% of claimants approve, the reorganization plan calls for a permanent injunction that will channel all future asbestos claims to the trust. Pfizer will fund the trust over a 40-year period through a note and $100 million in insurance

  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2004

E-mail this article
to a friend
Print this article
E-mail the editor